Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 6/20 | 0.59 |
| ▸ | EGFR | P00533 | 8/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 6/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | MLNR | O43193 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958163 | 0.90 | TEAD1 (0.71) | TEAD1EGFRDCUN1D1BTKEPHX2 | |
| SCHEMBL24780719 | 0.90 | TEAD1 (0.71) | TEAD1EGFRDCUN1D1BTKEPHX2 | |
| SCHEMBL21957254 | 0.90 | TEAD1 (0.71) | TEAD1EGFRDCUN1D1BTKEPHX2 | |
| SCHEMBL25785146 | 0.85 | EPHX2 (0.59) | TEAD1DCUN1D1BTKEPHX2MLNR | |
| SCHEMBL21958715 | 0.83 | TEAD1 (0.62) | TEAD1EGFRITKDCUN1D1BTK | |
| SCHEMBL21958750 | 0.83 | TEAD1 (0.62) | TEAD1EGFRITKDCUN1D1BTK | |
| SCHEMBL21958162 | 0.83 | TEAD1 (0.61) | TEAD1EGFRITKDCUN1D1BTK | |
| SCHEMBL21958157 | 0.80 | TEAD1 (0.60) | TEAD1EGFRDCUN1D1BTK | |
| SCHEMBL21958713 | 0.80 | EGFR (0.66) | TEAD1EGFRDCUN1D1BTKEPHX2 | |
| SCHEMBL21958183 | 0.80 | TEAD1 (0.60) | TEAD1EGFRDCUN1D1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885EGFR 3966/4885ITK 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.